Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 5Neuroendocrine Tumors 5Thyroid Cancer, Papillary 3Adenocarcinoma, Follicular 3Thyroid Neoplasms 2Paraganglioma, Extra-Adrenal 2Carcinoma, Medullary 2Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Thyroid Cancer Metastatic 1Pheochromocytoma 1Multiple Endocrine Neoplasia Type 1 1Differentiated Thyroid Cancer (DTC) 1Differentiated Thyroid Cancer 1Carcinoma, Neuroendocrine 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1Adrenocortical Carcinoma 1

Interventions

trametinib 1lenvatinib 1dabrafenib 1cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Differentiated Thyroid Cancer (DTC) × lenvatinib × Endocrine × Clear all
NCT02966093 2022-01-26

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Eisai Inc.

Phase 3 Completed
151 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡